UCSF

UC San Francisco Electronic Theses and Dissertations

Title

Associations Between Demographic, Clinical, and Symptom Characteristics and Stress in Oncology Patients Receiving Chemotherapy

Permalink

<https://escholarship.org/uc/item/6ds4q0ps>

Author

Stacker, Tara

Publication Date

2021

Peer reviewed|Thesis/dissertation

Associations Between Demographic, Clinical, and Symptom Characteristics and
Stress in Oncology Patients Receiving Chemotherapy

by
Tara Stacker

THESIS

Submitted in partial satisfaction of the requirements for degree of
MASTER OF SCIENCE

in

Nursing

in the

GRADUATE DIVISION

of the

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

Approved:

DocuSigned by:

Chris Miaskowski

Chris Miaskowski

4058DA2CA6554BB...

Chair

DocuSigned by:

Laura B. Dunn, M.D.

Laura B. Dunn, M.D.

DocuSigned by:

Kord Kober

Kord Kober

378C20C1146341A...

Committee Members

ACKNOWLEDGEMENTS

I would like to express my gratitude to my committee Chair, Dr. Christine Miaskowski, for her investment in my academic growth and for supporting my research pursuits. I value her mentorship; she sets a high bar and provides the guidance to succeed. I am grateful to my committee members, Dr. Laura Dunn and Dr. Kord Kober, who offered their much appreciated insights and encouragement. I give my thanks to Dr. Steven Paul, Dr. Jon Levine, Dr. Marilyn Hammer, and Dr. Yvette Conley, for their astute comments and expertise. I respectfully acknowledge my undergraduate mentor, Dr. Melanie McGrath, who inspired my engagement in research. I am also deeply grateful to my husband, children, colleagues, and friends, who made this academic milestone possible with their innumerable acts of caring and support.

CONTRIBUTIONS

This study was funded by a grant from the National Cancer Institute (CA134900). Dr. Miaskowski is an American Cancer Society Clinical Research Professor.

ABSTRACT

Associations Between Demographic, Clinical, and Symptom Characteristics and Stress in Oncology Patients Receiving Chemotherapy

By Tara Stacker

Most patients diagnosed with cancer and undergoing treatment experience global stress and cancer-specific stress. Both types of stress are associated with a higher symptom burden. Initial cancer diagnosis is regarded as a disease-specific traumatic event capable of provoking post-traumatic stress disorder (PTSD) symptoms. In this cross-sectional study, we used a comprehensive set of demographic, clinical, and symptom characteristics to evaluate their relative contribution to the severity of global and cancer-specific stress. Patients (n=941) completed study questionnaires prior to their second or third cycle of chemotherapy. Consistent with our a priori hypothesis, we found both common and distinct characteristics associated with higher levels of global stress and cancer-specific stress. A significant proportion of our patients had scores on the Impact of Event Scale-Revised (IES-R) suggestive subsyndromal (29.4%) or probable PTSD (13.9%). Four of the five stepwise linear regression analyses for the various stress scales explained between 41.6% and 54.5% of the total variance. Compared to various demographic and clinical characteristics, many of the common symptoms associated with cancer and its treatments uniquely explained a higher percentage of the variance in the various stress scales. Symptoms of depression made the largest unique contribution to the percentage of total explained variance across all five scales. Our findings suggest that clinicians need to assess for global stress, cancer-specific stress, and depression early after cancer diagnosis. Patients may benefit from integrative interventions (e.g., mindfulness-based stress reduction, cognitive behavioral therapy, acupuncture) that simultaneously address stress and symptoms commonly associated with cancer and its treatments.

TABLE OF CONTENTS

Introduction.....	1
Methods.....	3
Patients and Settings.....	3
Study Measures.....	3
Study Procedures.....	5
Data Analysis.....	6
Results.....	6
Demographic, Clinical, and Symptom Characteristics.....	6
Associations between Various Characteristics and Stress.....	7
Discussion.....	8
Limitations.....	12
Conclusions.....	12
References.....	13

LIST OF TABLES

TABLE 1: Demographic and Clinical Characteristics and Symptom Severity and Stress

Scores of the Sample (n=941).....21-22

TABLE 2: Effects of Select Demographic, Clinical, and Symptom Characteristics on Stress

Scores (n=941).....23

INTRODUCTION

Acute and chronic stress are associated with alterations in biology and behavior that result in poor health outcomes.^{1–3} A cancer diagnosis and its treatments are regarded as highly stressful events.⁴ Chronic stress can adversely impact patients' prognosis and their quality of life.^{5,6}

Multiple sources of stress can influence a patient's cancer trajectory. The initial diagnosis is considered a disease-specific traumatic event, that may provoke symptoms associated with post-traumatic stress disorder (PTSD).⁷ This cancer-specific stress is distinct from global stress that arises from the pressures of daily life.⁷ Most patients undergoing cancer treatment experience both types of stress.^{8,9} These findings provide a rationale for assessing global stress and cancer-specific stress, separately.

The Impact of Event Scale-Revised (IES-R) is often used to measure cancer-specific distress.^{10–13} Its three subscales assess intrusive thoughts, behavioral and cognitive avoidance, and hyperarousal, all symptoms that are consistent with traumatic stress. Previous research in varied research samples suggests that scores ≥ 24 differentiate stressed from non-stressed groups^{8,14} and scores ≥ 33 suggest probable PTSD.^{15,16} Several studies found that greater cancer-related stress is associated with a significantly higher physical and psychological symptom burden.^{14,17,18}

The Perceived Stress Scale (PSS) can capture additional information about the experience of stress among patients with cancer. Specifically, the PSS evaluates perceived global stress that arises from the environmental context in which a person is diagnosed and treated for cancer rather than from the cancer-related events themselves. Like cancer-specific stress, global perceived stress is associated with a higher symptom burden.¹⁷

Research on emotional adjustment to cancer found that global stress and cancer-specific stress have distinct effects. In a sample of women who underwent surgery for breast cancer, higher levels of cancer-specific stress were associated with post-traumatic growth,

whereas, higher levels of global stress demonstrated an inverse relationship with post-traumatic growth.¹⁹ In addition, in a study of patients with breast cancer,²⁰ global stress strongly predicted emotional adjustment compared to cancer-specific stress. Additional research is needed to understand the distinct characteristics associated with global and cancer-specific stress because they may warrant different interventions.

While unrelieved stress can have a negative impact on oncology patients,^{21–24} few studies have evaluated for common and unique demographic, clinical, and symptom characteristics associated with elevated levels of both global and cancer-specific stress. While younger age and unmarried/unpartnered status were associated with both types of stress,^{8,25} female gender, being White, and having a lower socioeconomic status were associated with higher cancer-related distress.⁸ In terms of clinical characteristics associated with stress, most studies have focused on patients with breast cancer. In a systematic review of 42 studies of breast cancer survivors,²⁶ a decreased functional status, a greater number of comorbidities, receipt of chemotherapy, and disease recurrence were associated with higher levels of psychological distress. In contrast, among newly diagnosed women with breast cancer, while clinical characteristics were not associated with cancer-specific distress, negative illness perceptions were a significant factor.²⁷ Regarding the relationships between stress and symptoms, a growing body of evidence suggests that higher levels of stress are associated with increases in pain,^{26,28} fatigue,^{26,29} sleep disturbance,^{26,28} chemotherapy-induced neurotoxicities,³⁰ depression,³¹ and cognitive impairment.^{32,33} Additional research is warranted to determine which demographic, clinical, and symptom characteristics are associated with global stress and/or disease-specific stress in oncology patients.

Therefore, the purpose of this study, in a large sample of oncology patients with heterogenous types of cancers (n=941), was to use the same set of demographic, clinical, and symptom characteristics to evaluate their relative contribution to the severity of global (i.e., PSS)

and cancer-related (i.e., IES-R) stress. We hypothesized that common and distinct characteristics would be associated with global and cancer-specific stress.

METHODS

Patients and Settings

This analysis used data from a descriptive, longitudinal study that evaluated the symptom experience of oncology outpatients receiving chemotherapy.³⁴ Eligible patients were ≥ 18 years of age; had a diagnosis of breast, gastrointestinal, gynecological, or lung cancer; had received chemotherapy within the preceding four weeks; were scheduled to receive at least two additional cycles of chemotherapy; and were able to read, write, and understand English. Recruitment was done at two Comprehensive Cancer Centers, one Veteran's Affairs hospital, and four community-based oncology programs. A total of 2234 patients were approached and 1343 consented to participate (60.1% response rate). Being overwhelmed with their cancer treatment was the primary reason for refusal. For this analysis, 941 patients with complete data were included.

Study Measures

Demographic and clinical characteristics

Patients completed a demographic questionnaire, the Karnofsky Performance Status (KPS) scale,^{35,36} and the Self-Administered Comorbidity Questionnaire (SCQ).³⁷ Medical records were reviewed for disease and treatment information. Toxicity of the chemotherapy regimen was evaluated using the MAX2 score.³⁸

Stress measures

The 14-item PSS measures global perceived stress as determined by the degree to which life circumstances are considered stressful over the previous week.³⁹ Each item was rated on a 0 to 4 Likert scale (i.e., 0 = never, 1 = almost never, 2 = sometimes, 3 = fairly often, 4 = very often). The PSS total score ranges from 0 to 56 with higher scores indicating greater stress. For the current study, its Cronbach's alpha was 0.85.

The 22-item IES-R measures cancer-related distress. Patients rated each item in terms of how distressing each potential stressor was over the past week with respect to their cancer and its treatment,⁴⁰ using a 0 to 4 Likert scale. Three subscales assess levels of intrusion, avoidance, and hyperarousal. The 7-item intrusion subscale evaluates intrusive recollections about the stressful experience. The 8-item avoidance subscale assesses the avoidance of situations related to the stressful experience. The 8-item hyperarousal subscale evaluates episodes of psychological arousal related to thoughts about the stressful event. Mean scores for each of the subscales is calculated and can range from 0 to 4.⁴¹ A total IES-R score can range from 0 to 88. Scores of ≥ 24 indicate clinically meaningful post-traumatic symptomatology and scores of ≥ 33 indicate probable PTSD.¹⁵ In the current study, the Cronbach's alpha for the total score was 0.92.

Symptom measures

The 20-item Center for Epidemiological Studies-Depression scale (CES-D) was used to assess depressive symptoms.⁴² Total scores can range from 0 to 60, with scores of ≥ 16 indicating the need for individuals to seek clinical evaluation for major depression. In the current study, its Cronbach's alpha was 0.89.

The 21-item Global Sleep Disturbance Scale (GSDS) assesses the quality of sleep over the past week.⁴³ Each item was rated on a 0 (never) to 7 (everyday) numeric rating scale (NRS). The total GSDS score can range from 0 (no disturbance) to 147 (extreme sleep disturbance). A higher total score indicates greater levels of sleep disturbance. A total score of ≥ 43 indicates a clinically meaningful level of sleep disturbance.⁴⁴ In the current study, its Cronbach's alpha was 0.83.

The 18-item Lee Fatigue Scale (LFS) assesses physical fatigue and energy. Items are rated on a 0 to 10 NRS with higher ratings indicating greater fatigue and higher levels of energy, respectively.⁴⁵ Total fatigue and energy scores were calculated as the mean of the 13 fatigue items and the 5 energy items. Using two separate LFS questionnaires, patients rated the items

in terms of how they felt within 30 minutes of awakening (i.e., morning fatigue, morning energy) and prior to going to bed (i.e., evening fatigue, evening energy). Established cut-off scores exist for clinically significant levels of fatigue (i.e., ≥ 3.2 for morning fatigue, ≥ 5.6 for evening fatigue) and energy (i.e., ≤ 6.2 for morning energy, ≤ 3.5 for evening energy).⁴⁴ In the current study, Cronbach's alphas were 0.96 for morning fatigue, 0.93 for evening fatigue, 0.95 for morning energy and 0.93 for evening energy.

The 16-item Attentional Function Index (AFI) assesses attentional function (i.e., perceived effectiveness with common activities requiring directed attention).⁴⁶ Items were rated on a 0 to 10 NRS with a higher total mean score indicating greater capacity to direct attention. Attentional function can be grouped into categories using the total score (i.e., < 5.0 low function, 5.0 to 7.5 moderate function, > 7.5 high function).⁴⁷ In the current study, its Cronbach's alpha was 0.93.

The Brief Pain Inventory (BPI) evaluated pain occurrence.⁴⁸ Patients responded yes if they had pain. If they responded yes, they were asked to indicate the cause(s) of their pain (i.e., only cancer, only non-cancer, or both cancer and non-cancer related pain).

Study Procedures

This study was approved by the Committee on Human Research at the University of California, San Francisco and by each study site. Eligible patients were approached by a research staff member in the infusion unit during their first or second cycle of chemotherapy to discuss participation in the study. Written informed consent was obtained from all patients. Depending on the length of their chemotherapy cycles, patients completed questionnaires in their homes, a total of six times over two cycles of chemotherapy. Data from the enrollment assessment were used in this analysis (i.e., prior to their second or third cycle of chemotherapy).

Data Analysis

Descriptive statistics and frequency distributions were generated for the demographic, clinical, and symptom characteristics and for the stress measures. All of the demographic, clinical, and symptom characteristics listed in Table 1 were evaluated in stepwise linear regressions to determine which characteristics were associated with higher stress scores. Although measured levels of anxiety were not included in the regressions given a high degree of collinearity with levels of depression. Separate regressions were done for each of the stress measures (i.e., PSS total score, IES-R total score, IES-R intrusion, IES-R avoidance, IES-R hyperarousal). For all the tests, a p-value of $<.05$ was considered statistically significant. All of the statistical analyses were done using SPSS version 27 (IBM Corporation, Armonk, NY).

RESULTS

Demographic, Clinical, and Symptom Characteristics

Patients in this study ($n=941$) were 56.6 (± 12.2) years of age and well educated. Most patients were female (77.6%), White (72.4%), and married or partnered (64.3%). About two-fifths of the patients had child care responsibilities (23.3%) or lived alone (22.2%). At enrollment, patients were 1.9 (± 3.7 ; median 0.42) years from diagnosis, had a mean KPS score of 80.0 (± 12.2), a mean SCQ score of 5.4 (± 3.0) and a mean MAX2 score of 0.17 (± 0.08). The most common comorbidities were high blood pressure (29.5%), back pain (23.9%), and depression (19.0%). Types of cancers included: breast (39%), gastrointestinal (31.3%), gynecological (18.8%), and lung (10.8%) with 1.3 (± 1.2) metastatic sites including lymph nodes (Table 1).

The symptom severity scores are summarized in Table 1. Patients had a mean CES-D score of 12.8 (± 9.6), below the cutoff that suggests the need for further evaluation for major depression. The mean score of 52.9 (± 20.0) for sleep disturbance exceeded the clinically meaningful cutoff. Mean scores for both morning 3.1 (± 2.2) and evening 5.4 (± 2.1) fatigue approached the clinically meaningful cutoff. The mean AFI score of 6.4 (± 1.8) suggests a

moderate level of attentional function. The majority of patients (55.6%) reported pain related to cancer and/or its treatment.

Associations between Various Characteristics and Stress

The mean PSS score of the sample was 18.4 (± 8.1). The mean IES-R total score was 18.6 (± 12.9). The results of the five stepwise regression analyses are shown in Table 2.

Characteristics Associated with Perceived Global Stress (PSS)

Five characteristics (i.e., younger age, having child care responsibilities, higher number of metastatic sites, higher level of depressive symptoms, lower attentional function) were associated with a higher level of perceived global stress. The final model explained 54.9% of the total variance.

Characteristics Associated with Cancer-Specific Stress (IES-R Total)

Seven characteristics (i.e., being unmarried/unpartnered, higher number of metastatic sites, having gastrointestinal versus breast cancer, and higher levels of depressive symptoms, sleep disturbance, and evening fatigue, and the occurrence of pain) were associated with higher levels of total cancer-specific stress. The final model explained 41.6% of the total variance.

Characteristics Associated with Avoidance (IES-R Avoidance)

Six characteristics (i.e., being unmarried/unpartnered, fewer years of education, lower body mass index, lower treatment-related toxicity, and higher levels of depressive symptoms and evening fatigue) were associated with higher levels of avoidance. The final model explained 15.6% of the total variance.

Characteristics Associated with Intrusion (IES-R Intrusion)

Six characteristics (i.e., being unmarried/unpartnered, higher number of metastatic sites, higher levels of depressive symptoms and sleep disturbance, lower levels of attentional function and occurrence pain) were associated with higher levels of avoidance. The final model explained 41.4% of the total variance.

Characteristics Associated with Hyperarousal (IES-R Hyperarousal)

Seven characteristics (i.e., younger age, living alone, higher levels of depressive symptoms, evening fatigue and sleep disturbance, lower levels of attentional function, and the occurrence of pain) were associated with higher levels of hyperarousal. The final model explained 49.1% of the total variance.

DISCUSSION

This study is the first to evaluate for associations between a consistent and comprehensive set of demographic, clinical, and symptom characteristics and multiple dimensions of stress in a large sample of oncology patients with heterogeneous types of cancers. Congruent with our a priori hypothesis, several common and distinct characteristics were associated with measures of global and disease-specific stress. Moreover, consistent with our a priori hypothesis and prior research,⁷ our findings suggest that global and cancer-specific stress are distinct types of stress.

Our patients' mean scores on the PSS (18.4 ± 8.1) and the IES-R (18.6 ± 12.9) are comparable to previous findings among oncology patients undergoing chemotherapy. For example, in a study that examined the relationship between stress and quality of life subsequent to cancer diagnosis and treatment among breast cancer patients,⁷ the mean PSS score was $18.13 (\pm 6.93)$ with a range of 0-36. In another study of the associations between global and cancer-specific stress and symptoms among cancer survivors,¹⁷ the mean PSS score was $17.3 (\pm 8.9)$ and approximately 8.2% of survivors reported an IES-R score of >33 . While the mean IES-R total score of our sample fell below the cutoff for probable PTSD, 29.4% of our patients had scores above the clinically meaningful cutoff score of ≥ 24.0 and 13.9% had scores ≥ 33.0 , suggestive of syndromal PTSD. Taken together, these findings suggest that a significant proportion of the patients in our study were experiencing clinically meaningful levels of cancer-specific stress.

Except for the IES-R Avoidance subscale (i.e., 15.6%), the remaining regression analyses explained between 41.6% (i.e., IES-R Total score) and 54.5% (i.e., PSS score) of the

total variance in the stress measures. As noted in one study,⁴⁹ compared to the IES-R Intrusion and Hyperarousal subscales, the items evaluated on the avoidance subscale do not fit the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria for PTSD. While the avoidance subscale focuses on active avoidance strategies, the DSM clusters the symptoms of avoidance and emotional numbing together. Therefore, given the small amount of explained variance for the avoidance subscale, future research needs to include additional characteristics (e.g., coping strategies, personality, mental adjustment to cancer) to determine their relative contribution to the severity of this type of stress.

A higher level of depressive symptoms was the only characteristic that was associated with higher levels of stress across all our measures and made the largest unique contribution to the percentage of explained variance. Depression uniquely explained between 13.3% and 20.1% of the total variance in the stress outcomes compared to the other statistically significant characteristics that often only uniquely explained less than 1% or not more than 3% of the total variance in the stress outcomes. This finding is congruent with the growing body of evidence that describes linkages between stress and depression.^{4,29,50} As noted in one review,⁵¹ prolonged stress can produce maladaptive neuroendocrine changes that can lead to the development of depression. Findings from other studies^{24,52} suggest that given the variety of biological processes that link depressive symptoms with sustained stress responses (e.g., dysregulation of the hypothalamic pituitary axis and the immune system; excessive activation of the sympathetic nervous system and excitatory neurotransmitters; loss of neuroplasticity), multiple feedback loops may occur that render it difficult to discern directionality.

Relative to the associations between various demographic and clinical characteristics, a number of the common symptoms associated with cancer and its treatments uniquely explained a higher percentage of the total variance in the various stress measures. Overall, our findings concur with previous studies that found positive associations between cognitive impairment,³³ pain,^{26,53} fatigue,^{54,55} sleep disturbance,⁵⁵ and stress. In terms of global stress, our results are

consistent with previous research that found that lower levels of attentional function were associated with higher levels of depressive symptoms.³³ In addition, our findings are congruent with previous studies that suggested that global stress from environmental factors cumulatively influences decrements in mental health and cognitive function.^{56,57} Further study is warranted to examine the potential impact of stress reduction strategies to improve mental health and cognition.

Our study found that, pain, fatigue, and sleep disturbance were associated with cancer-specific stress. Our findings are consistent with increasing evidence that demonstrates these three symptoms as well as depressive symptoms often occur as a cluster^{58,59} and are associated with cancer-specific stress.^{53,60,61} For example, in a study of patients with renal cell carcinoma,⁶¹ symptoms of depression and cancer-specific post-traumatic stress were independently associated with fatigue and sleep disturbance; moreover the associations with these two symptoms were even stronger when depression and cancer-related post-traumatic stress co-occurred. In addition, our findings are consistent with studies that reported on the co-occurrence of pain and PTSD symptoms.^{60,62} In one study of cancer survivors,⁵³ symptoms of PTSD were associated with the occurrence of chronic pain. Considered together, these associations between frequently co-occurring symptoms and global and cancer-specific stress highlight the need for continued research to investigate the mechanisms and directionality of these relationships.

In our study, the demographic characteristics associated with higher levels of global stress and cancer-specific stress were consistent with prior research. Similar to previous research that found an association between lower socioeconomic status and higher cancer-related distress,²⁶ we found an association between lower levels of education and higher levels of cancer-specific stress (i.e., higher IES-R Avoidance scores). Also consistent with previous reports,^{25,63,64} younger age was associated with higher levels of global and cancer-specific stress. Extending prior findings, our analyses of the IES-R subscales suggest that younger age

was associated with higher levels of hyperarousal but not with avoidance or intrusion. Living alone was associated uniquely with higher levels of hyperarousal. Further research is needed to determine whether these associations between younger age and living alone and higher IES-R Hyperarousal scores may reflect differences in illness perceptions, coping, and social support that could lessen typical symptoms of hyperarousal (e.g., anger, reckless behavior, exaggerated startle, hypervigilance).

While prior studies found that not being married/partnered was associated with higher levels of both global and disease specific stress,²⁵ our findings suggest that this characteristic was associated with only cancer-specific stress (i.e., higher IES-R total, avoidance, and intrusion scores). This finding may be explained by the emotional and practical support (e.g., accompaniment to appointments, treatment decisions, household chores) provided by spouses or partners that may mitigate some of the stress related to a cancer diagnosis and its treatment.

Of note, having child care responsibilities was the only characteristic associated with higher levels of global stress. These responsibilities increase the pressures of daily life (e.g., increased financial burden, role overload, relationship conflict) and contribute to overall life stress.⁶⁵ Future research needs to evaluate the efficacy of interventions that support caregiving responsibilities in an effort to reduce stress during cancer treatment.

Limited research exists on the associations between clinical characteristics and stress. While in one study, no associations were found,²⁷ in other studies, decrements in functional status,^{26,66} increased number of comorbidities,^{14,26} receipt of chemotherapy,²⁶ and disease recurrence²⁶ were associated with higher levels of stress. Among the clinical characteristics evaluated in this study, a higher number of metastatic sites including lymph node involvement was the only characteristic associated with both global and cancer-specific stress. This finding is most likely explained by the fact that the presence of metastatic disease is associated with changes in treatment⁶⁷ and/or a poorer prognosis.⁶⁸ It is not readily apparent why a lower BMI and a lower MAX2 score (i.e., less toxic chemotherapy regimen) were the two clinical

characteristics uniquely associated with higher avoidance scores. These findings warrant confirmation in future studies.

Limitations

Several limitations warrant consideration. While the sample size was large and heterogenous in terms of types of cancer, our findings may not generalize because the patients were predominantly women who were White, well educated, and earned a relatively high income. Therefore, our findings warrant replication in samples that are more representative of racial and ethnic diversity and other social determinants of health. Because of its cross-sectional design, no definitive conclusions can be drawn about the directionality of the associations found between various characteristics and stress.

Conclusions

In conclusion, our findings suggest that global stress and cancer-specific stress are distinct phenomena associated with both common as well as distinct demographic, clinical, and symptom characteristics. Depression was the only characteristic associated with both types of stress and all subscales of cancer-specific stress. Given the relationship between high stress and worse outcomes, early assessments of and interventions for global and disease-specific stress are warranted. Implications for practice include opportunities for clinicians to improve care by considering referrals for integrative approaches (e.g. mindfulness-based stress reduction, cognitive behavioral therapy, acupuncture) that may help address the complex relationships among cognitive-emotional⁶⁰ and physical symptoms⁶⁹ and stress.

REFERENCES

1. Saeedi M, Rashidy-Pour A. Association between chronic stress and Alzheimer's disease: Therapeutic effects of Saffron. *Biomed Pharmacother.* 2021;133:110995. doi:10.1016/j.biopha.2020.110995
2. Baritaki S, de Bree E, Chatzaki E, Pothoulakis C. Chronic Stress, Inflammation, and Colon Cancer: A CRH System-Driven Molecular Crosstalk. *J Clin Med.* 2019;8(10):1669. doi:10.3390/jcm8101669
3. Wirtz PH, von Känel R. Psychological Stress, Inflammation, and Coronary Heart Disease. *Curr Cardiol Rep.* 2017;19(11):111. doi:10.1007/s11886-017-0919-x
4. Smith HR. Depression in cancer patients: Pathogenesis, implications and treatment (Review). *Oncol Lett.* 2015;9(4):1509-1514. doi:10.3892/ol.2015.2944
5. Moreno-Smith M, Lutgendorf SK, Sood AK. Impact of stress on cancer metastasis. *Future Oncol.* 2010;6(12):1863-1881. doi:10.2217/fon.10.142
6. Cordova MJ, Riba MB, Spiegel D. Post-traumatic stress disorder and cancer. *The lancet Psychiatry.* 2017;4(4):330-338. doi:10.1016/S2215-0366(17)30014-7
7. Golden-Kreutz DM, Thornton LM, Wells-Di Gregorio S, et al. Traumatic stress, perceived global stress, and life events: prospectively predicting quality of life in breast cancer patients. *Health Psychol.* 2005;24(3):288-296. doi:10.1037/0278-6133.24.3.288
8. Langford DJ, Cooper B, Paul S, et al. Evaluation of coping as a mediator of the relationship between stressful life events and cancer-related distress. *Health Psychol.* 2017;36(12):1147-1160. doi:10.1037/hea0000524
9. Arnaboldi P, Riva S, Crico C, Pravettoni G. A systematic literature review exploring the prevalence of post-traumatic stress disorder and the role played by stress and traumatic stress in breast cancer diagnosis and trajectory. *Breast cancer (Dove Med Press.* 2017;9:473-485. doi:10.2147/BCTT.S111101
10. Carpenter KM, Fowler JM, Maxwell GL, Andersen BL. Direct and buffering effects of

- social support among gynecologic cancer survivors. *Ann Behav Med*. 2010;39(1):79-90.
doi:10.1007/s12160-010-9160-1
11. Salsman JM, Schalet BD, Andrykowski MA, Cella D. The impact of events scale: a comparison of frequency versus severity approaches to measuring cancer-specific distress. *Psychooncology*. 2015;24(12):1738-1745. doi:10.1002/pon.3784
  12. Civilotti C, Castelli L, Binaschi L, et al. Dissociative symptomatology in cancer patients. *Front Psychol*. 2015;6(FEB):118. doi:10.3389/fpsyg.2015.00118
  13. Chambers SK, Zajdlewicz L, Youlden DR, Holland JC, Dunn J. The validity of the distress thermometer in prostate cancer populations. *Psychooncology*. 2014;23(2):195-203.
doi:10.1002/pon.3391
  14. Miaskowski C, Paul SM, Snowberg K, et al. Stress and Symptom Burden in Oncology Patients During the COVID-19 Pandemic. *J Pain Symptom Manage*. 2020;60(5):e25-e34.
doi:10.1016/j.jpainsymman.2020.08.037
  15. Creamer M, Bell R, Failla S. Psychometric properties of the Impact of Event Scale - Revised. *Behav Res Ther*. 2003;41(12):1489-1496. doi:10.1016/j.brat.2003.07.010
  16. Morina N, Ehring T, Priebe S. Diagnostic utility of the impact of event scale-revised in two samples of survivors of war. *PLoS One*. 2013;8(12):e83916.
doi:10.1371/journal.pone.0083916
  17. Mazor M, Paul SM, Chesney MA, et al. Perceived stress is associated with a higher symptom burden in cancer survivors. *Cancer*. 2019;125(24):4509-4515.
doi:10.1002/cncr.32477
  18. Jakovljevic K, Kober KM, Block A, et al. Higher Levels of Stress Are Associated With a Significant Symptom Burden in Oncology Outpatients Receiving Chemotherapy. *J Pain Symptom Manage*. 2021;61(1):24-31.e4. doi:10.1016/j.jpainsymman.2020.07.019
  19. Groarke A, Curtis R, Kerin M. Global stress predicts both positive and negative emotional adjustment at diagnosis and post-surgery in women with breast cancer. *Psychooncology*.

- 2013;22(1):177-185. doi:10.1002/pon.2071
20. Groarke A, Curtis R, Groarke JM, Hogan MJ, Gibbons A, Kerin M. Post-traumatic growth in breast cancer: how and when do distress and stress contribute? *Psychooncology*. 2017;26(7):967-974. doi:10.1002/pon.4243
  21. Printz C. Psychological stress is associated with a higher risk of cervical cancer mortality. *Cancer*. 2020;126(2):240-241. doi:10.1002/cncr.32686
  22. Shin KJ, Lee YJ, Yang YR, et al. Molecular Mechanisms Underlying Psychological Stress and Cancer. *Curr Pharm Des*. 2016;22(16):2389-2402. doi:10.2174/1381612822666160226144025
  23. Kruk J, Aboul-Enein BH, Bernstein J, Gronostaj M. Psychological Stress and Cellular Aging in Cancer: A Meta-Analysis. *Oxid Med Cell Longev*. 2019;2019:1270397. doi:10.1155/2019/1270397
  24. Antoni MH, Dhabhar FS. The impact of psychosocial stress and stress management on immune responses in patients with cancer. *Cancer*. 2019;125(9):1417-1431. doi:10.1002/cncr.31943
  25. Miceli J, Geller D, Tsung A, et al. Illness perceptions and perceived stress in patients with advanced gastrointestinal cancer. *Psychooncology*. 2019;28(7):1513-1519. doi:10.1002/pon.5108
  26. Syrowatka A, Motulsky A, Kurteva S, et al. Predictors of distress in female breast cancer survivors: a systematic review. *Breast Cancer Res Treat*. 2017;165(2):229-245. doi:10.1007/s10549-017-4290-9
  27. Gibbons A, Groarke A, Sweeney K. Predicting general and cancer-related distress in women with newly diagnosed breast cancer. *BMC Cancer*. 2016;16(1):935. doi:10.1186/s12885-016-2964-z
  28. Liu H, Gao X, Hou Y. Effects of mindfulness-based stress reduction combined with music therapy on pain, anxiety, and sleep quality in patients with osteosarcoma. *Rev Bras*

- Psiquiatr.* 2019;41(6):540-545. doi:10.1590/1516-4446-2018-0346
29. Weber D, O'Brien K. Cancer and Cancer-Related Fatigue and the Interrelationships With Depression, Stress, and Inflammation. *J Evid Based Complementary Altern Med.* 2017;22(3):502-512. doi:10.1177/2156587216676122
  30. Miaskowski C, Paul SM, Mastick J, et al. Associations Between Perceived Stress and Chemotherapy-Induced Peripheral Neuropathy and Ototoxicity in Adult Cancer Survivors. *J Pain Symptom Manage.* 2018;56(1):88-97. doi:10.1016/j.jpainsymman.2018.02.021
  31. Linden W, Vodermaier A, Mackenzie R, Greig D. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. *J Affect Disord.* 2012;141(2-3):343-351. doi:10.1016/j.jad.2012.03.025
  32. Atallah M, Cooper B, Muñoz RF, et al. Psychological Symptoms and Stress Are Associated With Decrements in Attentional Function in Cancer Patients Undergoing Chemotherapy. *Cancer Nurs.* 2019;43(5):402-410. doi:10.1097/NCC.0000000000000713
  33. Henneghan A. Modifiable factors and cognitive dysfunction in breast cancer survivors: a mixed-method systematic review. *Support Care Cancer.* 2016;24(1):481-497. doi:10.1007/s00520-015-2927-y
  34. Miaskowski C, Cooper BA, Aouizerat B, et al. The symptom phenotype of oncology outpatients remains relatively stable from prior to through 1 week following chemotherapy. *Eur J Cancer Care (Engl).* 2017;26(3). doi:10.1111/ecc.12437
  35. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. *Cancer.* 1980;45(8):2220-2224. doi:10.1002/1097-0142(19800415)45:8<2220::aid-cnrcr2820450835>3.0.co;2-q
  36. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The Use of the Nitrogen Mustards in the Palliative Treatment of Carcinoma. *Cancer.* 1948;1(4):634-656. doi:10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L
  37. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity

- Questionnaire: a new method to assess comorbidity for clinical and health services research. *Arthritis Rheum.* 2003;49(2):156-163. doi:10.1002/art.10993
38. Extermann M, Bonetti M, Sledge GW, O'Dwyer PJ, Bonomi P, Benson AB. MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. *Eur J Cancer.* 2004;40(8):1193-1198.
doi:10.1016/j.ejca.2004.01.028
  39. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health Soc Behav.* 1983;24(4):385-396. doi:10.2307/2136404
  40. Weiss DS, Marmar C. The Impact of Event Scale-Revised. In: Wilson JP, Keane TM, eds. *Assessing Psychological Trauma and PTSD.* Guilford Press; 1997:399-411.
  41. Ristvedt SL, Trinkaus KM. Trait anxiety as an independent predictor of poor health-related quality of life and post-traumatic stress symptoms in rectal cancer. *Br J Health Psychol.* 2009;14(Pt 4):701-715. doi:10.1348/135910708X400462
  42. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. *Appl Psychol Meas.* 1977;1(3):385-401.
doi:10.1177/014662167700100306
  43. Lee KA, DeJoseph JF. Sleep disturbances, vitality, and fatigue among a select group of employed childbearing women. *Birth.* 1992;19(4):208-213. doi:10.1111/j.1523-536x.1992.tb00404.x
  44. Fletcher BS, Paul SM, Dodd MJ, et al. Prevalence, severity, and impact of symptoms on female family caregivers of patients at the initiation of radiation therapy for prostate cancer. *J Clin Oncol.* 2008;26(4):599-605. doi:10.1200/JCO.2007.12.2838
  45. Lee KA, Hicks G, Nino-Murcia G. Validity and reliability of a scale to assess fatigue. *Psychiatry Res.* 1991;36(3):291-298. doi:10.1016/0165-1781(91)90027-m
  46. Cimprich B, Visovatti M, Ronis DL. The Attentional Function Index--a self-report cognitive measure. *Psychooncology.* 2011;20(2):194-202. doi:10.1002/pon.1729

47. Cimprich B, So H, Ronis DL, Trask C. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. *Psychooncology*. 2005;14(1):70-78. doi:10.1002/pon.821
48. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. *Pain*. 1983;17(2):197-210. doi:10.1016/0304-3959(83)90143-4
49. Beck JG, Grant DM, Read JP, et al. The impact of event scale-revised: psychometric properties in a sample of motor vehicle accident survivors. *J Anxiety Disord*. 2008;22(2):187-198. doi:10.1016/j.janxdis.2007.02.007
50. Cruz-Pereira JS, Rea K, Nolan YM, O'Leary OF, Dinan TG, Cryan JF. Depression's Unholy Trinity: Dysregulated Stress, Immunity, and the Microbiome. *Annu Rev Psychol*. 2020;71:49-78. doi:10.1146/annurev-psych-122216-011613
51. Tafet GE, Nemeroff CB. The Links Between Stress and Depression: Psychoneuroendocrinological, Genetic, and Environmental Interactions. *J Neuropsychiatry Clin Neurosci*. 2016;28(2):77-88. doi:10.1176/appi.neuropsych.15030053
52. Gold PW. The organization of the stress system and its dysregulation in depressive illness. *Mol Psychiatry*. 2015;20(1):32-47. doi:10.1038/mp.2014.163
53. Sager ZS, Wachen JS, Naik AD, Moye J. Post-Traumatic Stress Disorder Symptoms from Multiple Stressors Predict Chronic Pain in Cancer Survivors. *J Palliat Med*. 2020;23(9):1191-1197. doi:10.1089/jpm.2019.0458
54. Park H, Kim K. Impact of Psycho-Social Factors on Fatigue among Breast Cancer Patients Who Are Currently Undergoing Radiotherapy. *Int J Environ Res Public Health*. 2020;17(17):1-13. doi:10.3390/ijerph17176092
55. Thekdi SM, Milbury K, Spelman A, et al. Posttraumatic stress and depressive symptoms in renal cell carcinoma: association with quality of life and utility of single-item distress

- screening. *Psychooncology*. 2015;24(11):1477-1484. doi:10.1002/pon.3758
56. Guidi J, Lucente M, Sonino N, Fava GA. Allostatic Load and Its Impact on Health: A Systematic Review. *Psychother Psychosom*. 2021;90(1):11-27. doi:10.1159/000510696
  57. Reid-Arndt SA, Cox CR. Stress, coping and cognitive deficits in women after surgery for breast cancer. *J Clin Psychol Med Settings*. 2012;19(2):127-137. doi:10.1007/s10880-011-9274-z
  58. Kwekkeboom K, Zhang Y, Campbell T, et al. Randomized controlled trial of a brief cognitive-behavioral strategies intervention for the pain, fatigue, and sleep disturbance symptom cluster in advanced cancer. *Psychooncology*. 2018;27(12):2761-2769. doi:10.1002/pon.4883
  59. Reilly CM, Bruner DW, Mitchell SA, et al. A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. *Support Care Cancer*. 2013;21(6):1525-1550. doi:10.1007/s00520-012-1688-0
  60. Bosco MA, Gallinati JL, Clark ME. Conceptualizing and Treating Comorbid Chronic Pain and PTSD. *Pain Res Treat*. 2013;2013:174728. doi:10.1155/2013/174728
  61. Thekdi SM, Milbury K, Spelman A, et al. Posttraumatic stress and depressive symptoms in renal cell carcinoma: association with quality of life and utility of single-item distress screening. *Psychooncology*. 2015;24(11):1477-1484. doi:10.1002/pon.3758
  62. Fishbain DA, Pulikal A, Lewis JE, Gao J. Chronic Pain Types Differ in Their Reported Prevalence of Post -Traumatic Stress Disorder (PTSD) and There Is Consistent Evidence That Chronic Pain Is Associated with PTSD: An Evidence-Based Structured Systematic Review. *Pain Med*. 2017;18(4):711-735. doi:10.1093/pm/pnw065
  63. Langford DJ, Cooper B, Paul S, et al. Distinct Stress Profiles Among Oncology Patients Undergoing Chemotherapy. *J Pain Symptom Manage*. 2020;59(3):646-657. doi:10.1016/j.jpainsymman.2019.10.025
  64. Avis NE, Levine BJ, Case LD, Naftalis EZ, Van Zee KJ. Trajectories of depressive

- symptoms following breast cancer diagnosis. *Cancer Epidemiol Biomarkers Prev.* 2015;24(11):1789-1795. doi:10.1158/1055-9965.EPI-15-0327
65. Nomaguchi K, Milkie MA. Parenthood and Well-Being: A Decade in Review. *J Marriage Fam.* 2020;82(1):198-223. doi:10.1111/jomf.12646
  66. Wong ML, Paul SM, Cooper BA, et al. Predictors of the multidimensional symptom experience of lung cancer patients receiving chemotherapy. *Support Care Cancer.* 2017;25(6):1931-1939. doi:10.1007/s00520-017-3593-z
  67. Yin Z, Tang H, Li L, et al. Impact of sites versus number of metastases on survival of patients with organ metastasis from newly diagnosed cervical cancer. *Cancer Manag Res.* 2019;11:7759-7766. doi:10.2147/CMAR.S203037
  68. Wang R, Zhu Y, Liu X, Liao X, He J, Niu L. The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. *BMC Cancer.* 2019;19(1):1091. doi:10.1186/s12885-019-6311-z
  69. Reich RR, Lengacher CA, Alinat CB, et al. Mindfulness-Based Stress Reduction in Post-treatment Breast Cancer Patients: Immediate and Sustained Effects Across Multiple Symptom Clusters. *J Pain Symptom Manage.* 2017;53(1):85-95. doi:10.1016/j.jpainsymman.2016.08.005

Table 1 - Demographic and Clinical Characteristics and Symptom Severity and Stress Scores of the Sample (n=941)

Characteristic	Mean (SD)
Age (years)	56.6 (12.2)
Education (years)	16.4 (3.0)
Body mass index (kg/m ²)	26.1 (5.6)
Karnofsky Performance Status score	80.0 (12.2)
Number of comorbidities	2.3 (1.4)
SCQ score	5.4 (3.0)
Time since cancer diagnosis (years)	1.9 (3.7)
Time since cancer diagnosis (median, years)	0.42
Number of prior cancer treatments	1.6 (1.5)
Number of metastatic sites including lymph node involvement	1.3 (1.2)
Number of metastatic sites excluding lymph node involvement	0.81 (1.1)
MAX2 score	0.17 (0.08)
	% (n)
Gender	
Female	77.6 (730)
Male	22.4 (211)
Ethnicity	
White	72.4 (681)
Non-white	27.6 (260)
Married or partnered (% yes)	64.3 (605)
Lives alone (% yes)	22.2 (209)
Child care responsibilities (% yes)	23.2 (218)
Care of adult responsibilities (% yes)	7.1 (63)
Currently employed (% yes)	36.6 (344)
Income	
<\$30,000	16.4 (154)
\$30,000 to <\$70,000	21.1 (199)
\$70,000 to <\$100,000	16.7 (157)
≥\$100,000	45.8 (431)
Specific comorbidities (% yes)	
Heart disease	5.1 (48)
High blood pressure	29.5 (278)
Lung disease	10.8 (102)
Diabetes	8.2 (77)
Ulcer or stomach disease	4.5 (42)
Kidney disease	1.7 (16)
Liver disease	6.4 (60)
Anemia or blood disease	11.8 (111)
Depression	19.0 (179)
Osteoarthritis	11.2 (105)
Back pain	23.9 (225)
Rheumatoid arthritis	2.6 (24)
Exercise on a regular basis (% yes)	71.4 (672)
Smoking current or history of (% yes)	34.5 (325)
Cancer diagnosis	
Breast	39.0 (367)
Gastrointestinal	31.3 (295)
Gynecological	18.8 (177)
Lung	10.8 (102)

Type of prior cancer treatment	
No prior treatment	24.0 (222)
Only surgery, CTX, or RT	41.9 (388)
Surgery & CTX, or Surgery & RT, or CTX & RT	21.4 (198)
Surgery & CTX & RT	12.7 (118)
CTX cycle length	
14-day cycle	44.2 (416)
21-day cycle	49.0 (461)
28-day cycle	6.8 (64)
Emetogenicity of CTX	
Minimal/Low	19.2 (181)
Moderate	60.8 (572)
High	20.0 (188)
Antiemetic regimens	
None	7.0 (64)
Steroid alone or serotonin receptor antagonist alone	20.6 (189)
Serotonin receptor antagonist and steroid	48.9 (449)
NK-1 receptor antagonist and two other antiemetics	23.6 (217)
Symptom severity scores ^a	Mean (SD)
Center for Epidemiological Studies-Depression Scale (≥ 16.0)	12.8 (9.6)
General Sleep Disturbance Scale (≥ 43.0)	52.9 (20.0)
Lee Fatigue Scale – Morning Fatigue (≥ 3.2)	3.1 (2.2)
Lee Fatigue Scale – Evening Fatigue (≥ 5.6)	5.4 (2.1)
Attentional Function Index (< 5 = low, $5-7.5$ = moderate, > 7.5 = high)	6.4 (1.8)
	% (n)
Occurrence of pain related to cancer and/or its treatment (% yes)	55.6 (523)
Stress scale scores	
Perceived Stress Scale	18.4 (8.1)
Impact of Event Scale – Revised – Intrusion	0.90 (0.70)
Impact of Event Scale – Revised – Avoidance	0.93 (0.68)
Impact of Event Scale – Revised – Hyperarousal	0.66 (0.66)
Impact of Event Scale – Revised – Total score (≥ 24.0)	18.6 (12.9)

Abbreviations: CTX = chemotherapy, kg = kilograms, m² = meters squared, NK-1 = Neurokinin-1, RT = radiation therapy, SCQ = Self-administered Comorbidity Questionnaire, SD = standard deviation

^a Numbers in parentheses indicate clinically meaningful cutpoints for the symptom and stress measures.

Table 2 – Effects of Select Demographic, Clinical, and Symptom Characteristics on Stress Scores (n=941)

PERCEIVED STRESS SCALE – TOTAL SCORE					
Characteristic	R ²	r	β	R ² -change (sr ²)	p-value
Overall	.549	---	---	---	<.001
Age	---	-.214	-.075	.005	.002
Child care responsibilities	---	.121	.056	.003	.018
Number of metastatic sites	---	.011	.047	.002	.033
Depressive symptoms	---	.709	.558	.194	<.001
Attentional function	---	-.575	-.226	.032	<.001
IMPACT OF EVENT SCALE - REVISED – TOTAL SCORE					
Characteristic	R ²	r	β	R ² -change (sr ²)	p-value
Overall	.416	---	---	---	<.001
Married/partnered	---	-.052	.089	.007	.001
Number of metastatic sites	---	.021	.042	.002	.104
GI versus breast cancer	---	.040	.080	.005	.005
Depressive symptoms	---	.618	.565	.201	<.001
Sleep disturbance	---	.439	.160	.016	<.001
Evening fatigue	---	.191	-.078	.005	.006
Occurrence of pain (no versus yes)	---	-.221	-.057	.003	.030
IMPACT OF EVENT SCALE - REVISED – AVOIDANCE SUBSCALE SCORE					
Characteristic	R ²	r	β	R ² -change (sr ²)	p-value
Overall	.156	---	---	---	<.001
Married/partnered	---	-.002	.080	.006	.009
Level of education	---	-.115	-.088	.007	.004
Body mass index	---	-.044	-.067	.004	.028
MAX2 score	---	-.036	-.069	.005	.023
Depressive symptoms	---	.356	.404	.133	<.001
Evening fatigue	---	.046	-.088	.007	.007
IMPACT OF EVENT SCALE - REVISED – INTRUSION SUBSCALE SCORE					
Characteristic	R ²	r	β	R ² -change (sr ²)	p-value
Overall	.414	---	---	---	<.001
Married/partnered	---	-.046	.090	.008	<.001
Number of metastatic sites	---	.044	.078	.006	.002
Depressive symptoms	---	.612	.585	.181	<.001
Sleep disturbance	---	.443	.168	.018	<.001
Attentional function	---	-.337	.109	.007	.001
Occurrence of pain (no versus yes)	---	-.243	-.076	.005	.004
IMPACT OF EVENT SCALE - REVISED – HYPERAROUSAL SUBSCALE SCORE					
Characteristic	R ²	R	β	R ² -change (sr ²)	p-value
Overall	.491	---	---	---	<.001
Age	---	-.189	-.057	.003	.019
Lives alone	---	.004	-.065	.004	.006
Depressive symptoms	---	.665	.501	.133	<.001
Sleep disturbance	---	.510	.183	.020	<.001
Attentional function	---	-.494	-.104	.006	.001
Evening fatigue	---	.249	-.069	.004	.009
Occurrence of pain (no versus yes)	---	-.075	-.269	.005	.002

Publishing Agreement

It is the policy of the University to encourage open access and broad distribution of all theses, dissertations, and manuscripts. The Graduate Division will facilitate the distribution of UCSF theses, dissertations, and manuscripts to the UCSF Library for open access and distribution. UCSF will make such theses, dissertations, and manuscripts accessible to the public and will take reasonable steps to preserve these works in perpetuity.

I hereby grant the non-exclusive, perpetual right to The Regents of the University of California to reproduce, publicly display, distribute, preserve, and publish copies of my thesis, dissertation, or manuscript in any form or media, now existing or later derived, including access online for teaching, research, and public service purposes.

DocuSigned by:

Tara Stacker

44DAAA9BFB01439...

Author Signature

5/19/2021

Date